The FDA’s leading advisory board has voted unanimously on the safety and efficacy of the HPV vaccine Gardasil. HPV causes up to two-thirds of cervical cancer cases, which kills 290,000 women every year worldwide.

With the expectation of the FDA to follow the advisory board’s approval of the drug, Gardasil may be on sale in the U.S. by the end of the summer.

Of course, the drug will really only be accessible to people who can afford the $650 in treatments that it would cost.

Nevertheless, this is good news. Let’s just hope that the political forces behind the FDA approve as well.